Discover why Altimmune (ALT) and Viking Therapeutics (VKTX) are top picks for high-risk investors. Click here to read my most ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and upcoming MASH results may be fueling excitement.

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of ...

Altimmune Inc. (ALT) reported its first-quarter 2025 financial results, revealing a narrower-than-expected loss. The company’s reported earnings per share (EPS) were -$0.26, surpassing analyst ...

Altimmune, Inc., a late clinical-stage biopharmaceutical company, announced that it will release its first quarter 2025 financial results on May 13, 2025. A conference call to discuss these ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled ...

Altimmune, Inc. announced new analyses at the EASL Congress in Amsterdam, showcasing the MASH Resolution Index (MASHResInd) algorithm, developed by Dr. Rohit Loomba, to predict resolution in ...